

# Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

## CWR22Pc

RRID:CVCL\_LI38

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_LI38

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_LI38](https://web.expasy.org/cellosaurus/CVCL_LI38)

**Proper Citation:** RRID:CVCL\_LI38

**Description:** Cell line CWR22Pc is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Prostate carcinoma

**Defining Citation:** [PMID:18829484](#), [PMID:21248069](#), [PMID:27271795](#)

**Comments:** Characteristics: Androgen-dependent. Expresses full-length AR and PSA., Population: Caucasian.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** CWR22Pc

**Cross References:** cancercellines:CVCL\_LI38, Wikidata:Q54817055

**ID:** CVCL\_LI38

**Hierarchy:** cvcl\_3967

**Record Creation Time:** 20220427T215607+0000

**Record Last Update:** 20260905T174813+0000

---

### Ratings and Alerts

No rating or validation information has been found for CWR22Pc.

No alerts have been found for CWR22Pc.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Nayak S, et al. (2026) Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 224.

Detlefsen AJ, et al. (2023) AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3 $\beta$ ,17 $\beta$ -Diol. Cancer research communications, 3(9), 1888.

Salji MJ, et al. (2022) Multi-omics & pathway analysis identify potential roles for tumor N-acetyl aspartate accumulation in murine models of castration-resistant prostate cancer. iScience, 25(4), 104056.